GlassScriptPhysician profile
Daniel Jason Fredericks
NPI 1669991717
$4,226.42
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,029 · 2022: $1,243 · 2023: $1,232 · 2024: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.73 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $443.27 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $427.05 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $402.49 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neos Therapeutics, LP | $379.71 | 2021-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $310.13 | 2021-2023 | Rexulti |
| Corium, LLC | $293.40 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.79 | 2022-2024 | Caplyta |
| Tris Pharma INC | $146.97 | 2021-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $105.56 | 2021-2024 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $101.30 | 2023-2024 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $95.46 | 2023-2024 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $87.38 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $78.82 | 2022-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $44.75 | 2021-2024 | Invega Sustenna, Invega Trinza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $32.17 | 2023-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $21.70 | 2021 | |
| Adlon Therapeutics L.P. | $20.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fredericks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.